GlobalData on MSN

ModeX starts dosing in MDX2003 trial for B-cell lymphoma

The trial includes dose-escalation and dose-expansion segments.
The Manila Times

OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas

Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomas ...